If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has tirzepatide treatment been studied in people with class IV congestive heart failure?
There is no information on the use of tirzepatide in people with type 2 diabetes and class IV congestive heart failure because this has not been studied.
Boxed Warning
See important safety information, including boxed warning, in the attached prescribing information.
Use in Patients With Congestive Heart Failure Class IV
There is no information on the use of tirzepatide in patients with a history of class IV congestive heart failure. In the SURPASS clinical program of tirzepatide for type 2 diabetes, participants were excluded if they had a history of class IV congestive heart failure.1
Enclosed Prescribing Information
Reference
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: November 03, 2023